AndrewSFeiginMD

Neurology • New York, NY

Professor, Neurology, NYU Langone Health

Join to view full profile

Dr. Feigin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Feigin's full profile

Already have an account?

Office
222 E 41st St
Fl 13
New York, NY 10017
Phone+1 212-263-4838

Education & Training

University of RochesterResidency, Neurology, 1989 - 1992
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1988 - 1989
Columbia University Vagelos College of Physicians and SurgeonsClass of 1988

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1992 - 2025
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013

Clinical Trials

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) Start of enrollment: 2009 Sep 01
Terminated
Phase 3

Publications & Presentations

PubMed

Rescue Lead Implantation After Deep Brain Stimulation for Parkinson's Disease: A Single-Center Experience and Case Series.
Zane Schnurman, Arash Fazl, Andrew S Feigin, Alon Y Mogilner, Michael Pourfar
Operative Neurosurgery. 2024-09-01
5 citations
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Ralf Reilmann, Karen E Anderson, Andrew Feigin, Sarah J Tabrizi, Blair R Leavitt
The Lancet. Neurology. 2024-03-01
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Andrew Feigin, Elizabeth E Evans, Terrence L Fisher, John E Leonard, Ernest S Smith
Nature Medicine. 2024-02-01

Press Mentions

AAN 2023: Pridopidine Phase 3 Trial Misses Goal, but Benefits Seen for SomeMay 2nd, 2023
Prilenia Shares Preliminary Topline Results from Phase 3 PROOF-HD Clinical Trial in Huntington's Disease and Data from Phase 2 HEALEY ALS Platform Trial of Pridopidine at the 75th American Academy of Neurology (AAN) Annual MeetingApril 25th, 2023
Parkinson’s Cases May Be 50% Higher Than Previously Thought: Why That’s Important to KnowDecember 15th, 2022
Join now to see all

Professional Memberships

American Academy of Neurology - AAN
Member